Skip to content

Comparison of Continuous Bupivacaine Wound Infiltration Versus Bupivacaine-Ketamine and Bupivacaine-Magnesium Admixtures for Postoperative Analgesia Following Caesarean Section Under Spinal Anaesthesia

Comparison of Continuous Bupivacaine Wound Infiltration Versus Bupivacaine-Ketamine and Bupivacaine-Magnesium Admixtures for Postoperative Analgesia Following Caesarean Section Under Spinal Anaesthesia

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
PACTR
Registry ID
PACTR202607539615815
Enrollment
93
Registered
2026-07-22
Start date
2026-08-01
Completion date
Unknown
Last updated
2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth Anaesthesia

Interventions

Bupivacaine 0.5 percent with Ketamine 0.2mgperKg
Bupivacaine 0.5percent and Magnesium Sulphate 6000mg

Sponsors

Dr Ayodeji Oluwatominiyi
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Patients aged 18–40 years undergoing elective cesarean section using a Pfannenstiel incision under a subarachnoid block. 2. American Society of Anesthesiologists (ASA) physical status class II. 3. Patients capable of understanding and using the Visual Analogue Scale (VAS). 4. Patients who have consented to the study

Exclusion criteria

Exclusion criteria: EXCLUSION CRITERIA 1. Patient refusal. 2. Known allergy to any study drug (bupivacaine, magnesium sulfate, ketamine, or morphine). 3. Compromised renal, hepatic, or cardiac function; bleeding disorder; skeletal muscle disorder; or neurological deficit. 4. History of drug or alcohol abuse. 5. Obesity (BMI > 30 kg/m²). 6. Long-term treatment with magnesium. 7. History of chronic pain or current treatment for chronic pain. 8. Patients unsuitable for subarachnoid block or cases converted to sedation or general anesthesia.

Design outcomes

Primary

MeasureTime frame
Postoperative pain score (VAS)

Secondary

MeasureTime frame
Total morphine consumption in 24 hours;Time to first rescue analgesia;Incidence of adverse effects of study drugs;Patient Satisfaction

Countries

Nigeria

Contacts

Public ContactOlumuyiwa Ajayeoba

Consultant Anaesthetist

ajayeobatope@gmail.com+2348068805517

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026